[144] Olema Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Shane W. Kovacs filed a notice of proposed sale of securities on Form 144 covering up to 100,000 shares of common stock. The shares are planned to be sold through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 01/15/2026 and an indicated aggregate market value of $2,873,214.99. The filing notes that 68,659,923 common shares were outstanding.

The shares to be sold were acquired between 2020 and 2024 through restricted stock vesting, open market purchases, and employee stock purchase plan (ESPP) purchases from the issuer. The notice also reports that during the past three months, Kovacs sold 3,822 common shares on 01/13/2026 for $107,069.20 in gross proceeds.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	100000	2873214.99	68659923	01/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/15/2020	Restricted Stock Vesting	Issuer			26961	06/15/2020	Compensation
Common	09/02/2022	Open Market Purchase	Issuer			20000	09/02/2022	Cash
Common	04/06/2023	Open Market Purchase	Issuer			10000	04/06/2023	Cash
Common	05/15/2023	ESPP Purchase	Issuer			9034	05/15/2023	Cash
Common	11/15/2023	ESPP Purchase	Issuer			1748	11/15/2023	Cash
Common	06/28/2024	ESPP Purchase	Issuer			471	06/28/2024	Cash
Common	12/09/2024	Restricted Stock Vesting	Issuer			16017	12/09/2024	Compensation
Common	12/10/2024	Restricted Stock Vesting	Issuer			15769	12/10/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Shane W. Kovacs 780 Brannan Street San Francisco CA 94103	Common	01/13/2026	3822	107069.20

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)